TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on the development of natural, plant-based active ingredients, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. All amounts in this press release are in U.S. dollars. Corporate Update Following the reconstitution of the Company’s board of directors (the “Board”) on May 30, 2025, th ...

In this article, we will look at the 10 Most Profitable S&P 500 Stocks to Buy Now.Profitability has moved back to the center of the market conversation. After a stretch where narratives were driven by multiple expansions and AI-linked optimism, attention has started to shift toward companies that can consistently generate earnings regardless of the macro backdrop. That shift is showing up in how investors talk about resilience, not just revenue growth, but margins, return profiles, and the ability to compou ...

Is ELV a good stock to buy? We came across a bullish thesis on Elevance Health, Inc. on Grillo Insights’s Substack by Eric García. In this article, we will summarize the bulls’ thesis on ELV. Elevance Health, Inc.'s share was trading at $289.24 as of March 23rd. ELV’s trailing and forward P/E were 11.56 and 11.39 respectively according to Yahoo Finance. easiest LPN to RN bridge programs michaeljung/Shutterstock.com Elevance Health, Inc., together with its subsidiaries, operates as a health benefits compa ...

Alignment Healthcare is a Medicare Advantage provider leveraging a technology-driven platform to deliver personalized healthcare to seniors. With operations concentrated in select U.S. states, the company differentiates itself through consumer-centric service and integrated care coordination.Did market conditions play a material role in the timing or pricing of this transaction? Shares were sold at around $17.48 per share, consistent with the closing price of $17.51 on March 23, 2026; this price level refle ...

The advertising company founded by industry veteran Martin Sorrell projected in-line revenue performance for 2026 and higher profitability. ...

RT DeLord 💎 (@Defi_lord002)🔥 𝐒𝐓𝐎𝐏 𝐋𝐎𝐒𝐈𝐍𝐆 𝐏𝐑𝐎𝐅𝐈𝐓𝐒 𝐓𝐎 𝐅𝐄𝐄𝐒 𝐏𝐎𝐋𝐎𝐍𝐈𝐄𝐗 𝐈𝐒 𝐑𝐄𝐖𝐑𝐈𝐓𝐈𝐍𝐆 𝐓𝐇𝐄 𝐑𝐔𝐋𝐄𝐒In trading, everyone talks about strategy, entries, and market timing… but one of the biggest hidden killers of profit is fees.Not the obvious ones — the silent ones that slowly drain your gains over time.That’s why this milestone matters:👉 Poloniex has processed 34.64M USDT in ZERO-FEE tradesThis isn’t hype.This is real volume, real traders, real savings.📊 𝗪𝗛𝗬 𝗧𝗛𝗜𝗦 𝗜𝗦 𝗔 𝗚𝗔𝗠𝗘 𝗖𝗛𝗔𝗡𝗚𝗘𝗥Every trade you make:• Entry → fee• Ex ...

EXCLUSIVE: In Starz‘s Q4 earnings report in February, the company called 2026 a “positive financial inflection point,” saying it would focus on profitability and generating positive free cash flow after its separation from Lionsgate. In addition to OTT subscriber growth and increasing content ownership, cost-reduction inevitably is part of the equation. That includes staff cuts. Starz underwent a round of layoffs Friday that impacted 7% of the company’s employees, Deadline has learned. The move, which is b ...

Winterhoff said the Lucid Air was the number one best-selling EV in its luxury sedan segment in 2025 and ranked third in the broader luxury sedan segment including internal combustion vehicles. He added that Gravity is “off to a good start,” citing production momentum in late 2025 and comparisons to early delivery trajectories of other premium EV SUVs. He also pointed to award recognition, including both Air and Gravity appearing on Car and Driver’s 10 Best list for 2026, and said Lucid has received more aw ...

Core Insights - Investors should focus on companies that provide strong returns after considering all operating and non-operating expenses, with profitable businesses being more attractive than those with losses [1] - NVIDIA Corporation (NVDA) and Micron Technology, Inc. (MU) are highlighted as top profitable picks due to their strong net income ratios and significant upside potential [2] Profitability Metrics - The net income ratio is a key indicator of a company's profitability, representing the percentage of net income relative to total sales revenues, with a higher ratio indicating better revenue generation and expense management [3] - Additional screening parameters include Zacks Rank 1 (Strong Buy), trailing 12-month sales and net income growth higher than the industry, and a strong buy percentage rating greater than 70% [4][5] Company Performance - NVIDIA has a 12-month net profit margin of 55.6%, indicating strong revenue efficiency [6][8] - Micron Technology has a 12-month net profit margin of 41.5%, reflecting solid profitability in the memory and storage sector [7][8]

Core Insights - BioSyent Inc. reported strong financial results for Q4 and FY 2025, with total company revenue growth of 23% year-over-year, driven by both Canadian and international pharmaceutical sales [1][2]. Financial Performance - Q4 2025 Canadian Pharma Sales reached CAD 8,792,653, a 3% increase from Q4 2024, while FY 2025 Canadian Pharma Sales totaled CAD 37,143,783, reflecting a 13% increase from FY 2024 [1]. - International Pharma Sales surged to CAD 601,387 in Q4 2025, marking a 240% increase year-over-year, and FY 2025 International Pharma Sales reached CAD 3,735,959, up 302% from FY 2024 [1]. - Legacy Business Sales saw a significant rise, with Q4 2025 sales of CAD 277,883, up 278%, and FY 2025 sales of CAD 2,172,241, an 86% increase [1]. - Total Company Sales for Q4 2025 were CAD 9,671,923, a 10% increase, and for FY 2025, total sales were CAD 43,051,983, a 23% increase [1]. - EBITDA for Q4 2025 was CAD 2,528,561, up 13%, and for FY 2025, it was CAD 12,122,756, reflecting a 30% increase [1][6]. - Net Income After Taxes (NIAT) for Q4 2025 was CAD 1,991,788, a 23% increase, and for FY 2025, it was CAD 9,012,232, up 24% [1][6]. Strategic Initiatives - The company continues to invest in its key products, including FeraMAX and Tibella/Tibelia, which have been significant revenue drivers [2]. - BioSyent has maintained a healthy NIAT margin of 21% for FY 2025 and has a track record of 62 consecutive profitable quarters [2]. - The company completed the acquisition of Oral Science Inc., expanding its portfolio in the oral health sector [4]. Shareholder Returns - BioSyent repurchased 19,500 common shares under a Normal Course Issuer Bid (NCIB) during FY 2025 and increased its quarterly dividend by 10% to CAD 0.055 per common share, paid on March 13, 2026 [4].